Wilson Therapeutics appoints Vincent Metzler as Vice President Commercial Planning & Launch Strategy

Wilson Therapeutics AB (publ), announces the appointment of Vincent Metzler as
Vice President Commercial Planning & Launch Strategy. Dr Metzler will report to
CEO Jonas Hansson and will join the company’s management team.

Dr Metzler is a senior marketing & commercial operations executive with an
extensive rare disease background and more than 16 years of experience in the
pharmaceutical and biotech industries. Most recently Dr Metzler served as Senior
Director Marketing at Alexion where he was responsible for and played an
instrumental role in launching and building the commercial success of Soliris in
the EMEA region. Soliris is the world’s most successful non-oncology orphan
product with more than $2.5 billion in world-wide sales in 2015. At Alexion Dr
Metzler developed and implemented the marketing strategy for 7 of the largest
markets in the global Soliris business and he was a core member of the Global
Soliris Leadership Team. Prior to Alexion Dr Metzler held various sales and
marketing positions at Miltenyi Biotec, Roche and Amgen. Dr Metzler received his
MSc in Chemistry & Biology from Louis Pasteur University in Strasbourg and his
PhD in Molecular Biology from the University of Bern.

“I am very excited to join Wilson Therapeutics,” said Vincent Metzler. “With my
strong passion for bringing innovative medicines to patients suffering from rare
diseases, I see this as a unique opportunity to make our highly promising
product candidate available to patients affected by the debilitating Wilson
Disease who still are in significant need for effective and well-tolerated
treatment options.”

“I am very pleased to welcome Vincent to our executive team,” said Jonas
Hansson, CEO of Wilson Therapeutics. “Vincent brings a wealth of global
marketing & commercialization expertise in the rare disease field with a proven
track record, having been responsible for the commercial success of Soliris in
Europe. His knowledge and experience will be tremendously valuable for us as we
prepare for a future potential launch of Decuprate®.”

About Wilson Therapeutics
Wilson Therapeutics is a biopharmaceutical company, based in Stockholm, Sweden,
that develops novel therapies for patients with rare diseases. Wilson
Therapeutics’ lead product, Decuprate®, is initially being developed as a novel
treatment for Wilson Disease and is currently being evaluated in a Phase II
clinical study. Wilson Therapeutics is listed in the Mid Cap segment on Nasdaq
Stockholm with the stock ticker WTX.

Visit www.wilsontherapeutics.com for more information.

For further information contact:
Jonas Hansson, CEO, Wilson Therapeutics AB
Telephone: +46 8 796 00 00
Email: jonas.hansson@wilsontx.eu

Wilson Therapeutics AB (publ)
Org nr 556893-0357
Västra Trädgårdsgatan 15
SE-111 53 Stockholm

The information in the press release is information that Wilson Therapeutics is
obliged to make public pursuant to the EU Market Abuse Regulation. The
information was submitted for publication, through the agency of the contact
person set out above, at 08.30 CET on August 15, 2016.